Amyloidosis News and Research RSS Feed - Amyloidosis News and Research

Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
New imaging technique may help detect amyloid-related heart failure

New imaging technique may help detect amyloid-related heart failure

A type of heart failure caused by a build-up of amyloid can be accurately diagnosed and prognosticated with an imaging technique, eliminating the need for a biopsy, according to a multicenter study led by researchers at Columbia University Medical Center. [More]
Long-term antibiotic treatment slows progression of Alzheimer's disease through changes in gut bacteria

Long-term antibiotic treatment slows progression of Alzheimer's disease through changes in gut bacteria

Long-term treatment with broad spectrum antibiotics decreased levels of amyloid plaques, a hallmark of Alzheimer's disease, and activated inflammatory microglial cells in the brains of mice in a new study by neuroscientists from the University of Chicago. [More]
TSRI study reveals new approach to intervene in deadly disease

TSRI study reveals new approach to intervene in deadly disease

In a new study, scientists at The Scripps Research Institute have identified drug candidates that can boost a cell's ability to catch the "typos" in protein production that can cause a deadly disease called amyloidosis. [More]
JAD announces recipient of 2016 Alzheimer Award

JAD announces recipient of 2016 Alzheimer Award

The Journal of Alzheimer's Disease is pleased to announce that Mark W. Bondi, PhD, ABPP/CN, Professor of Psychiatry at UC San Diego and Director of the Neuropsychological Assessment Unit at the VA San Diego Healthcare System, has been chosen as the recipient of the 2016 Alzheimer Award presented by the journal in recognition of his outstanding work on the development of a novel and promising method of staging preclinical Alzheimer's disease (AD) based on number of abnormal biomarkers that is predictive of progression to mild cognitive impairment (MCI) and AD. [More]
Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis). [More]
Novel animal model helps understand mechanisms that lead to multiple myeloma

Novel animal model helps understand mechanisms that lead to multiple myeloma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. The study was published in the journal Scientific Reports. [More]
Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Cairn Diagnostics, formerly known as Advanced Breath Diagnostics (ABDiagnostics), has launched the 13C-Spirulina Gastric Emptying Breath Test (GEBT). [More]

New molecular probe can detect different amyloid deposits in human tissues

A team of scientists at Sweden's Linköping University have developed a molecular probe that can detect an array of different amyloid deposits in several human tissues. This new probe is extremely sensitive and was used at very low concentrations to correctly identify every positive amyloidosis sample when compared to the traditional clinical tests. [More]
Scientists find evidence that amyloid fibrils adopt several distinct architectures in human, animal tissues

Scientists find evidence that amyloid fibrils adopt several distinct architectures in human, animal tissues

Formation of amyloid fibrils is a characteristic feature of neurogenerative diseases like Alzheimer's. As published in the journal Angewandte Chemie, German and American scientists have found evidence that these fibrils adopt several distinct three-dimensional architectures in real patient and animal tissues. [More]
Cause of amyloid beta pathology may be more versatile than previously known

Cause of amyloid beta pathology may be more versatile than previously known

Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications. [More]
TTR protein causes autoimmune reaction in joints of juvenile idiopathic arthritis patients

TTR protein causes autoimmune reaction in joints of juvenile idiopathic arthritis patients

Juvenile idiopathic arthritis, or JIA, is the most common form of childhood arthritis. It appears to be an autoimmune disease, caused by antibodies attacking certain proteins in a person's own tissue. But no "autoantigens" -- the proteins triggering an immune attack -- have been linked to JIA. [More]
SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona (IBB-UAB), in collaboration with the biopharmaceutical company SOM Biotech, located in the Barcelona Science Park (PCB), have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug, SOM0226 (tolcapone) that could significantly improve the pharmacological treatment of familial transthyretin amyloidosis (ATTR). [More]
Astrocytes implicated in preclinical AD

Astrocytes implicated in preclinical AD

Astrocytes are activated in the brains of people with autosomal dominant Alzheimer’s disease long before symptoms appear and even before amyloidosis begins, a study shows. [More]
Unlocking intrinsically disordered proteins: an interview with Peter Wright

Unlocking intrinsically disordered proteins: an interview with Peter Wright

I'm a professor in the Department of Integrative Structural and Computational Biology at The Scripps Research Institute. I have been performing NMR research on proteins for nearly 40 years. [More]
ISHLT issues new list of criteria to determine patient eligibility for heart transplant

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians. [More]
FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

Ionis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD). [More]
Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Research that leads to improved therapies for Alzheimer's disease (AD) patients is one goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was one of six researchers awarded a two-year, $500,000 award in Alzheimer's Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation. [More]
Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Isis Pharmaceuticals, Inc. today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1 Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
Study reveals how MGCs dispose waste that obstructs normal physiological processes

Study reveals how MGCs dispose waste that obstructs normal physiological processes

If rubbish is too big and unwieldy for normal household waste, its removal becomes the job of specialized experts. Researchers from the Technical University of Munich (TUM) have now discovered, in cooperation with colleagues from the UK, how large, fused cells help our body to deal with bulky items that may otherwise obstruct normal physiological processes. [More]
Advertisement